ERIS Lifesciences Ltd
ERISERIS Lifesciences Ltd's earnings have outrun its stock. EPS grew +73.1% in a year against a −17.4% price move.
The sharpest disagreement: annual EPS moved +73.1% against a −17.4% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (25 weeks in) while the P/E sits at the 55th percentile of its own 9-year range. Underneath, the last four quarters read improving — profit +173.5% year on year, and 147% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
ERIS Lifesciences Ltd trades at ₹1,455, in a downtrend and 25 weeks into that stage. That is +1.2% against its own 200-day average. It sits at 33% of a 52-week range of ₹1,285 to ₹1,800. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a downtrend — week 25 of stage 4, confirmed. At ₹1,455 it trades +1.2% versus its 200-day average and sits at 33% of its 52-week range (₹1,285–₹1,800).
Against the market, two honest reads. Cumulative: over the last 9.0 years the stock moved +142% while the NIFTY 500 moved +176% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 55th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
ERIS Lifesciences Ltd trades at 30.7× P/E, mid-range by its own standards (55th percentile). Its long-run median P/E is 29.7×, measured across 9.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.7× is mid-range by its own standards (55th percentile), against a long-run median of 29.7× measured over 9.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +73.1% against a −17.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +13.6%/yr price move, ~+11.8%/yr came from earnings growth and ~+1.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 11% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
ERIS Lifesciences Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −13.9% at the trough to +173.5% off a 5-quarter-old trough (single-quarter readings), ROCE holding at 14.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.1% | +22.9% | +20.9% | +18.0% |
| Profit | +72.8% | +20.1% | +12.8% | +17.0% |
| EPS | +73.1% | +16.8% | +11.3% | −41.6% |
| Share price | −17.4% | +26.8% | +13.6% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
51.3/100 — rank 21 of 43 in Pharma - Formulators · 73% evidence confidence
ERIS Lifesciences Ltd scores 51.3 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 21. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.5 + 12.8 + 10.5 + 5.5 = 51.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
ERIS Lifesciences Ltd reported ₹757 Cr of revenue in the Mar 26 quarter, +7.4% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 18.0% a year. The last full year, FY26, came in at ₹3,129 Cr. The last four reported quarters add to ₹3,129 Cr.
ERIS Lifesciences Ltd reported ₹757 Cr of revenue in the Mar 26 quarter, +7.4% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 18.0% a year. The last full year, FY26, came in at ₹3,129 Cr. The last four reported quarters add to ₹3,129 Cr.
FY26 revenue came in at ₹3,129 Cr (+8.1% on the year), capping 10 years at 18.0% compound. The latest quarter (Mar 26) printed ₹757 Cr, +7.4% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.2% growth against the decade's 18.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.2% over the last 4 quarters against +24.8%/yr over the last 8 — rolling over; TTM profit +72.5% vs +27.7%/yr — accelerating.
→ Revenue grew — did margins hold as it scaled? Next: 36.0% this quarter (+0.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
ERIS Lifesciences Ltd's operating margin is 36.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 19.0% to 38.0%. The current quarter sits inside that band.
ERIS Lifesciences Ltd's operating margin is 36.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 19.0% to 38.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 36.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 19.0%–38.0%.
Why the margin moved: operating margin went +0.2 pp year on year while gross margin went −0.3 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +173.5% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
ERIS Lifesciences Ltd earned ₹279 Cr of net profit in the Mar 26 quarter, +173.5% year on year. It is the 5th consecutive quarter of growth. Full-year FY26 profit was ₹648 Cr. The 10-year compound rate is 17.0%. That is 36.9% of the quarter's revenue. The same quarter a year earlier earned ₹102 Cr.
ERIS Lifesciences Ltd earned ₹279 Cr of net profit in the Mar 26 quarter, +173.5% year on year. It is the 5th consecutive quarter of growth. Full-year FY26 profit was ₹648 Cr. The 10-year compound rate is 17.0%. That is 36.9% of the quarter's revenue. The same quarter a year earlier earned ₹102 Cr.
Mar 26 profit was ₹279 Cr, +173.5% year on year — the 5th consecutive quarter of growth. On the full year, FY26 printed ₹648 Cr (+72.8%), and the 10-year compound rate is 17.0%.
Why profit moved: revenue contributed +7.4% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +69.3% vs revenue +8.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 147% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 147% of ERIS Lifesciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹538 Cr of operating cash against ₹648 Cr of profit. After ₹266 Cr of capital spending, ₹272 Cr was left as free cash.
FY26: operating cash of ₹538 Cr against reported profit of ₹648 Cr, leaving free cash of ₹272 Cr after ₹266 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 147% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 147%: the cash cycle stretched 99 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 4.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹3,547 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
ERIS Lifesciences Ltd's cash conversion cycle runs 129 days in FY26, up from 30 days in FY21. Capital spending ran ₹3,547 Cr over the last 3 years. At FY26 sales of ₹3,129 Cr each day of that cycle holds about ₹8.6 Cr, so roughly ₹1,106 Cr sits inside the business at any moment.
FY26: debtors at 79 days, inventory at 200 days — roughly 6.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 129 days, looser than FY21's 30.
The full loop: cash goes out to suppliers and production on day 0; stock waits 200 days to sell; customers pay about 79 days after that; and suppliers themselves are paid at 151 days — netting out to the 129-day cycle.
In money terms: at FY26 sales of ₹3,129 Cr, each day of the cycle holds about ₹8.6 Cr — so the 129-day loop keeps roughly ₹1,106 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹3,547 Cr over the last 3 fiscal years against ₹778 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹171 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 14%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
ERIS Lifesciences Ltd earns a ROCE of 14% in FY26. That is up from a trough of 11% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 20.7% net margin on 0.42× asset turns.
FY26 ROCE is 14%, recovered from a FY24 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 20.7% net margin × 0.42× asset turns × 1.89× balance-sheet leverage ≈ 16.4% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 11% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.60.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
ERIS Lifesciences Ltd carries ₹2,359 Cr of borrowings against ₹3,903 Cr of equity in FY26, a debt-to-equity of 0.60. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹7.0 Cr to ₹2,359 Cr. Capital spending ran ₹3,547 Cr across the last 3 of those years.
FY26: borrowings of ₹2,359 Cr against equity of ₹3,903 Cr — a debt-to-equity of 0.60. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹7.0 Cr to ₹2,359 Cr while capital spending ran ₹3,547 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 11% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Foreign institutions cut 8.8 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 8.8 points of ERIS Lifesciences Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 5.8% of the company. Domestic institutions moved +4.5 points over the same window, to 20.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −8.8 points over 8 quarters to 5.8%; Domestic institutions: +4.5 points over 8 quarters to 20.7%; Promoters: −0.7 points over 8 quarters to 54.1%.
Why the register moved: rotation — foreign institutions −8.8 points against domestic institutions +4.5 points over 8 quarters, with promoters −0.7 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
ERIS Lifesciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| ERIS Lifesciences Ltd this page | 30.7× | ₹19,409 Cr | Turning around | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is ERIS Lifesciences Ltd's share price today?
ERIS Lifesciences Ltd trades at ₹1,455, −17.4% over the past year. The company is valued at ₹19,409 Cr. The stock sits at 33% of its 52-week range of ₹1,285–₹1,800, +1.2% versus its 200-day average. On the tape, the price is in a downtrend, 25 weeks in. — as of 24 July 2026.
What were ERIS Lifesciences Ltd's latest quarterly results?
ERIS Lifesciences Ltd reported revenue of ₹757 Cr and net profit of ₹279 Cr for the Mar 26 quarter. Revenue rose 7.4% and profit rose 173.5% year on year. Earnings per share were ₹20.33. The operating margin was 36.0%, 0.0 pp higher than a year earlier. — as of 24 July 2026.
What is ERIS Lifesciences Ltd's revenue?
ERIS Lifesciences Ltd reported revenue of ₹757 Cr in the Mar 26 quarter, +7.4% year on year. For the full FY26 fiscal year, revenue was ₹3,129 Cr (+8.1%). Over the last 10 years revenue compounded at 18.0% a year. — as of 24 July 2026.
What is ERIS Lifesciences Ltd's profit?
ERIS Lifesciences Ltd earned ₹279 Cr of net profit in the Mar 26 quarter, +173.5% year on year — the 5th straight quarter of growth. Full-year FY26 profit was ₹648 Cr. The operating margin ran 36.0% in the latest quarter. — as of 24 July 2026.
What is ERIS Lifesciences Ltd's market cap?
ERIS Lifesciences Ltd's market capitalisation is ₹19,409 Cr at a share price of ₹1,455. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is ERIS Lifesciences Ltd's P/E ratio?
ERIS Lifesciences Ltd trades at a P/E of 30.7×, at the 55th percentile of its own 9-year range, against a long-run median of 29.7×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does ERIS Lifesciences Ltd pay a dividend?
Yes — ERIS Lifesciences Ltd's dividend payout was 16% of profit in FY26, and it recorded a payout in 7 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is ERIS Lifesciences Ltd overvalued?
On its own history, ERIS Lifesciences Ltd looks mid-range against its own history: its P/E of 30.7× sits at the 55th percentile of its 9-year range (long-run median 29.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is ERIS Lifesciences Ltd growing?
Yes — ERIS Lifesciences Ltd is growing: latest-quarter revenue +7.4% year on year, profit +173.5%, and the margin +0.0 pp at 36.0%. The 10-year compound rates are 18.0% (revenue) and 17.0% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is ERIS Lifesciences Ltd performing?
ERIS Lifesciences Ltd is in a downtrend, 25 weeks in. Its latest quarter's revenue rose 7.4% and profit rose 173.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is ERIS Lifesciences Ltd in?
Turning around — profit growth swung from −13.9% at the trough to +173.5% off a 5-quarter-old trough (single-quarter readings), ROCE holding at 14.0%. The read comes from the last 12 quarters of growth (revenue growth +7.4% latest, profit growth +173.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is ERIS Lifesciences Ltd in an uptrend?
No — the price is in a downtrend (week 25 of stage 4), trading +1.2% versus its 200-day average and at 33% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is ERIS Lifesciences Ltd beating the market?
On recent form, yes — ERIS Lifesciences Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 9.0 years the stock moved +142% against the NIFTY 500's +176% — behind the index over the full window. — as of 24 July 2026.
Will ERIS Lifesciences Ltd's share price go up?
This page publishes no price forecast for ERIS Lifesciences Ltd. What it measures instead: the share price is ₹1,455, the price is in a downtrend 25 weeks in. Its P/E of 30.7× sits at the 55th percentile of its own 9-year range. — as of 24 July 2026.
Who owns ERIS Lifesciences Ltd?
Promoters hold 54.1% of ERIS Lifesciences Ltd, foreign institutions 5.8%, domestic institutions 20.7% and the public 19.4% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 8.8 points over 8 quarters. — as of 24 July 2026.
Does ERIS Lifesciences Ltd have too much debt?
It is moderate — ERIS Lifesciences Ltd's debt-to-equity is 0.60, and operating profit covers the interest bill 6×. FY26 borrowings were ₹2,359 Cr against equity of ₹3,903 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is ERIS Lifesciences Ltd's capex?
ERIS Lifesciences Ltd spent ₹3,547 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹266 Cr, with ₹171 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is ERIS Lifesciences Ltd's cash flow?
ERIS Lifesciences Ltd generated ₹538 Cr of operating cash flow in FY26 and ₹272 Cr of free cash flow after ₹266 Cr of capital spending. Reported profit that year was ₹648 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is ERIS Lifesciences Ltd's profit real cash?
Yes — over the last 3 fiscal years, 147% of ERIS Lifesciences Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹538 Cr against reported profit of ₹648 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is ERIS Lifesciences Ltd in its business cycle?
ERIS Lifesciences Ltd's FY26 operating margin was 36.0%, against a 13-year band of 19.0%–38.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 36.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the ERIS Lifesciences Ltd story?
The sharpest disagreement: annual EPS moved +73.1% against a −17.4% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is ERIS Lifesciences Ltd a stock worth studying right now?
This is not investment advice. The machine read: ERIS Lifesciences Ltd's earnings have outrun its stock. EPS grew +73.1% in a year against a −17.4% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.